Date: 2016-03-14
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Eli Lilly (USA - IN)
Product: merestinib (LY2801653)
Action
mechanism: c-Met inhibitor. Merestinib is a small molecule inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. Merestinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
Disease: biliary tract cancer
Therapeutic area: Cancer - Oncology
Country: Argentina, Australia, Austria, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Italy, Republic of Korea, Mexico, Russian Federation, Spain, Sweden, Taiwan, Turkey, UK, USA
Trial
details: The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer. (NCT02711553)
Latest
news: * On March 14, 2016, a Phase 2 trial sponsored by Eli Lilly was published on the NIH website ClinicalTrials.gov merestinib (LY2801653) and is currently recruiting participants.
